The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

Magdalena Paolino, Axel Choidas, Stephanie Wallner, Blanka Pranjic, Iris Uribesalgo, Stefanie Loeser, Amanda M. Jamieson, Wallace Y. Langdon, Fumiyo Ikeda, Juan Pablo Fededa, Shane J. Cronin, Roberto Nitsch, Carsten Schultz-Fademrecht, Jan Eickhoff, Sascha Menninger, Anke Unger, Robert Torka, Thomas Gruber, Reinhard Hinterleitner, Gottfried BaierDominik Wolf, Axel Ullrich, Bert M. Klebl, Josef M. Penninger

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies2. Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology3. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a a 'pill' that awakens the innate immune system to kill cancer metastases.

Original languageEnglish
Pages (from-to)508-512
Number of pages5
JournalNature
Volume507
Issue number7493
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Ubiquitin-Protein Ligases
Natural Killer Cells
Lymphoma
Neoplasm Metastasis
Neoplasms
Immune System
Natural Killer Cell Receptors
Ubiquitination
Warfarin
Licensure
Therapeutics
Anticoagulants
Melanoma
Phosphotransferases
Breast Neoplasms
Mortality

All Science Journal Classification (ASJC) codes

  • General

Cite this

Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., ... Penninger, J. M. (2014). The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature, 507(7493), 508-512. https://doi.org/10.1038/nature12998

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. / Paolino, Magdalena; Choidas, Axel; Wallner, Stephanie; Pranjic, Blanka; Uribesalgo, Iris; Loeser, Stefanie; Jamieson, Amanda M.; Langdon, Wallace Y.; Ikeda, Fumiyo; Fededa, Juan Pablo; Cronin, Shane J.; Nitsch, Roberto; Schultz-Fademrecht, Carsten; Eickhoff, Jan; Menninger, Sascha; Unger, Anke; Torka, Robert; Gruber, Thomas; Hinterleitner, Reinhard; Baier, Gottfried; Wolf, Dominik; Ullrich, Axel; Klebl, Bert M.; Penninger, Josef M.

In: Nature, Vol. 507, No. 7493, 01.01.2014, p. 508-512.

Research output: Contribution to journalArticle

Paolino, M, Choidas, A, Wallner, S, Pranjic, B, Uribesalgo, I, Loeser, S, Jamieson, AM, Langdon, WY, Ikeda, F, Fededa, JP, Cronin, SJ, Nitsch, R, Schultz-Fademrecht, C, Eickhoff, J, Menninger, S, Unger, A, Torka, R, Gruber, T, Hinterleitner, R, Baier, G, Wolf, D, Ullrich, A, Klebl, BM & Penninger, JM 2014, 'The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells', Nature, vol. 507, no. 7493, pp. 508-512. https://doi.org/10.1038/nature12998
Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Jan 1;507(7493):508-512. https://doi.org/10.1038/nature12998
Paolino, Magdalena ; Choidas, Axel ; Wallner, Stephanie ; Pranjic, Blanka ; Uribesalgo, Iris ; Loeser, Stefanie ; Jamieson, Amanda M. ; Langdon, Wallace Y. ; Ikeda, Fumiyo ; Fededa, Juan Pablo ; Cronin, Shane J. ; Nitsch, Roberto ; Schultz-Fademrecht, Carsten ; Eickhoff, Jan ; Menninger, Sascha ; Unger, Anke ; Torka, Robert ; Gruber, Thomas ; Hinterleitner, Reinhard ; Baier, Gottfried ; Wolf, Dominik ; Ullrich, Axel ; Klebl, Bert M. ; Penninger, Josef M. / The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. In: Nature. 2014 ; Vol. 507, No. 7493. pp. 508-512.
@article{b27c29a41ac248f58bebcd26fc50d354,
title = "The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells",
abstract = "Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies2. Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology3. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a a 'pill' that awakens the innate immune system to kill cancer metastases.",
author = "Magdalena Paolino and Axel Choidas and Stephanie Wallner and Blanka Pranjic and Iris Uribesalgo and Stefanie Loeser and Jamieson, {Amanda M.} and Langdon, {Wallace Y.} and Fumiyo Ikeda and Fededa, {Juan Pablo} and Cronin, {Shane J.} and Roberto Nitsch and Carsten Schultz-Fademrecht and Jan Eickhoff and Sascha Menninger and Anke Unger and Robert Torka and Thomas Gruber and Reinhard Hinterleitner and Gottfried Baier and Dominik Wolf and Axel Ullrich and Klebl, {Bert M.} and Penninger, {Josef M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/nature12998",
language = "English",
volume = "507",
pages = "508--512",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7493",

}

TY - JOUR

T1 - The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

AU - Paolino, Magdalena

AU - Choidas, Axel

AU - Wallner, Stephanie

AU - Pranjic, Blanka

AU - Uribesalgo, Iris

AU - Loeser, Stefanie

AU - Jamieson, Amanda M.

AU - Langdon, Wallace Y.

AU - Ikeda, Fumiyo

AU - Fededa, Juan Pablo

AU - Cronin, Shane J.

AU - Nitsch, Roberto

AU - Schultz-Fademrecht, Carsten

AU - Eickhoff, Jan

AU - Menninger, Sascha

AU - Unger, Anke

AU - Torka, Robert

AU - Gruber, Thomas

AU - Hinterleitner, Reinhard

AU - Baier, Gottfried

AU - Wolf, Dominik

AU - Ullrich, Axel

AU - Klebl, Bert M.

AU - Penninger, Josef M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies2. Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology3. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a a 'pill' that awakens the innate immune system to kill cancer metastases.

AB - Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies2. Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology3. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a a 'pill' that awakens the innate immune system to kill cancer metastases.

UR - http://www.scopus.com/inward/record.url?scp=84897954522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897954522&partnerID=8YFLogxK

U2 - 10.1038/nature12998

DO - 10.1038/nature12998

M3 - Article

C2 - 24553136

AN - SCOPUS:84897954522

VL - 507

SP - 508

EP - 512

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7493

ER -